Niina M. Saarinen

Niina M. Saarinen

Auto-generated profile, based on publicly available information

Niina M. Saarinen

Functional Foods Forum, University of Turku, Turku, Finland

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Natural Product Reports
Verified
Journal Article
Closed access
PDF file
MKMilla Kibble
Milla Kibble
NSNiina Saarinen
Niina Saarinen
Jing TangJing Tang
Jing Tang
KWKrister Wennerberg
Krister Wennerberg
SMSari Mäkelä
Sari Mäkelä
TATero Aittokallio
Tero Aittokallio
Covering: 2011 to 2014 It is widely accepted that drug discovery often requires a systems-level polypharmacology approach to tackle problems such as lack of efficacy and emerging resistance of single-targeted compounds. Network pharmacology approaches are increasingly being developed and applied to find new therapeutic opportunities and to re-purpose approved drugs. However, these recent advances have been relatively slow to be translated into the field of natural products. Here, we argue that a network pharmacology approach would enable an effective mapping of the yet unexplored target space of natural products, hence providing a systematic means to extend the druggable space of proteins implicated in various complex diseases. We give an overview of the key network pharmacology concepts and recent experimental–computational approaches that have been successfully applied to natural product research, including unbiased elucidation of mechanisms of action as well as systematic prediction of effective therapeutic combinations. We focus specifically on anticancer applications that use in vivo and in vitro functional phenotypic measurements, such as genome-wide transcriptomic response profiles, which enable a global modelling of the multi-target activity at the level of the biological pathways and interaction networks. We also provide representative examples of other disease applications, databases and tools as well as existing and emerging resources, which may prove useful for future natural product research. Finally, we offer our personal view of the current limitations, prospective developments and open questions in this exciting field.

1 April 2006 in The Journal of Nutrition
Verified
Journal Article
Open access
PDF file
ZLZhen Liu
Zhen Liu
NSNiina M. Saarinen
Niina M. Saarinen
LTLILIAN THOMPSON
LILIAN THOMPSON
Plant lignans occur in many foods, with flaxseed presently recognized as the richest source. Some plant lignans can be converted by intestinal microbiota to the mammalian lignans, enterodiol and enterolactone, which may have protective effects against hormone-related diseases such as breast cancer. This study determined whether plant lignans in sesame seed, particularly sesamin, could be metabolized to the mammalian lignans. The total plant lignan concentration in sesame seed (2180 μmol/100 g) was higher than that in flaxseed (820 μmol/100 g). In vitro fermentation with human fecal inoculum showed conversion of sesamin to the mammalian lignans, although at a lower rate (1.1%) compared with that of secoisolariciresinol diglucoside (57.2%). However, when fed to female Sprague-Dawley rats for 10 d, sesamin (15 mg/kg body weight) and a 10% sesame seed diet resulted in greater (P < 0.05) urinary mammalian lignan excretion (3.2 and 11.2 μmol/d, respectively), than the control (< 0.05 μmol/d). We conclude that sesame seed is a rich source of mammalian lignan precursors and sesamin is one of them. From intermediate metabolites of sesamin identified in rat urine by GC-MS, a tentative metabolic pathway of sesamin to mammalian lignans is suggested.

1 March 2000 in Nutrition and Cancer
Verified
Journal Article
Closed access
NSN. M. Saarinen
N. M. Saarinen
AWA. Warri
A. Warri
SMS. I. Makela
S. I. Makela
CEC. Eckerman
C. Eckerman
MRM. Reunanen
M. Reunanen
RSR. Santti
R. Santti
The potential for the extraction of the plant lignan hydroxymatairesinol (HMR) in large scale from Norway spruce (Picea abies) has given us the opportunity to study the metabolism and biological actions of HMR in animals. HMR, the most abundant single component of spruce lignans, was metabolized to enterolactone (ENL) as the major metabolite in rats after oral administration. The amounts of urinary ENL increased with the dose of HMR (from 3 to 50 mg/kg), and only minor amounts of unmetabolized HMR isomers and other lignans were found in urine. HMR (15 mg/kg body wt po) given for 51 days decreased the number of growing tumors and increased the proportion of regressing and stabilized tumors in the rat dimethylbenz[a]anthracene-induced mammary tumor model. HMR (50 mg/kg body wt) did not exert estrogenic or antiestrogenic activity in the uterine growth test in immature rats. HMR also showed no antiandrogenic responses in the growth of accessory sex glands in adult male rats. Neither ENL nor enterodi...

8 April 2008 in British Journal of Cancer
Verified
Journal Article
Open access
AWA Warri
A Warri
NSN M Saarinen
N M Saarinen
SMS Makela
S Makela
Leena Hilakivi-ClarkeLeena Hilakivi-Clarke
Leena Hilakivi-Clarke
Review of the existing literature suggests that consumption of soy foods or an exposure to a soy isoflavone genistein during childhood and adolescence in women, and before puberty onset in animals, reduces later mammary cancer risk. In animal studies, an exposure that is limited to the fetal period or adult life does not appear to have the same protective effect. A meta-analysis of human studies indicates a modest reduction in pre- and postmenopausal risk when dietary intakes are assessed during adult life. These findings concur with emerging evidence indicating that timing may be vitally important in determining the effects of various dietary exposures on the susceptibility to develop breast cancer. In this review, we address the mechanisms that might mediate the effects of an early life exposure to genistein on the mammary gland. The focus is on changes in gene expression, such as those involving BRCA1 and PTEN. It will be debated whether mammary stem cells are the targets of genistein-induced alterations and also whether the alterations are epigenetic. We propose that the effects on mammary gland morphology and signalling pathways induced by pubertal exposure to genistein mimic those induced by the oestrogenic environment of early first pregnancy.

2 July 2007 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
NSNiina M. Saarinen
Niina M. Saarinen
AWAnni Wärri
Anni Wärri
MAMaarit Airio
Maarit Airio
ASAnnika Smeds
Annika Smeds
SMSari Mäkelä
Sari Mäkelä

1 April 2018 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
MHMerja R. Häkkinen
Merja R. Häkkinen
THTaija Heinosalo
Taija Heinosalo
NSNiina Saarinen
Niina Saarinen
TLTero Linnanen
Tero Linnanen
RVRaimo Voutilainen
Raimo Voutilainen
SASeppo Auriola
Seppo Auriola